HEMATOLOGIC SAFETY PROFILE OF SINGLE-AGENT CARFILZOMIB IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA FROM FOUR PHASE 2 STUDIES

被引：0
|
作者：
Nooka, A. [1 ]
机构：
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
来源：
HAEMATOLOGICA | 2012年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1515
引用
收藏
页码：601 / 601
页数：1
相关论文
共 50 条
  • [1] Hematologic safety data from four phase II studies of single-agent carfilzomib in relapsed and/or refractory multiple myeloma
    Nooka, Ajay K.
    Badros, Ashraf Z.
    Patel, Priti
    McCulloch, Leanne
    Lonial, Sagar
    Kaufman, Jonathan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [2] Cardiac and pulmonary safety profile of patients with relapsed and/or refractory multiple myeloma from four phase 2 studies of single-agent carfilzomib
    Lonial, Sagar
    Niesvizky, Ruben
    McCulloch, Leanne
    Rajangam, Kanya
    Vij, Ravi
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 : 19 - 19
  • [3] Cardiac and Pulmonary Safety Profile of Single-Agent Carfilzomib From Four Phase 2 Studies in Patients with Relapsed and/or Refractory Multiple Myeloma
    Lonial, Sagar
    Niesvizky, Ruben
    McCulloch, Leanne
    Rajangam, Kanya
    Vij, Ravi
    [J]. BLOOD, 2012, 120 (21)
  • [4] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase 2 trials
    Siegel, D. S.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lonial, S.
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2013, 161 : 20 - 20
  • [5] Safety profile of single-agent carfilzomib in patients with relapsed or refractory multiple myeloma from 4 phase ll trials
    Siegel, D.
    Martin, T.
    Nooka, A.
    Harvey, R. D.
    Vij, R.
    Niesvizky, R.
    Badros, A. Z.
    Jagannath, S.
    McCulloch, L.
    Rajangam, K.
    Lenial, S.
    [J]. ONKOLOGIE, 2013, 36 : 39 - 40
  • [6] Management of Hematologic Adverse Events in Patients With Relapsed and/or Refractory Multiple Myeloma Treated With Single-Agent Carfilzomib
    Nooka, Ajay K.
    [J]. ONCOLOGY-NEW YORK, 2013, 27 : 11 - 18
  • [7] Safety and efficacy of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma
    Richardson, Paul
    Jagannath, Sundar
    Hussein, Mohamad
    Berenson, James
    Singhal, Seema
    Irwin, David
    Williams, Stephanie F.
    Bensinger, William
    Badros, Ashraf Z.
    Vescio, Robert
    Kenvin, Laurie
    Yu, Zhinuan
    Olesnyckyj, Marta
    Zeldis, Jerome
    Knight, Robert
    Anderson, Kenneth C.
    [J]. BLOOD, 2009, 114 (04) : 772 - 778
  • [8] Summary of treatment-emergent renal events from patients treated with single-agent carfilzomib from four phase II studies in relapsed and/or refractory multiple myeloma.
    Harvey, R. Donald
    Lonial, Sagar
    Patel, Priti
    McCulloch, Leanne
    Niesvizky, Ruben
    Kaufman, Jonathan L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [9] Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib
    Harvey, R. Donald
    [J]. CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2014, 6 : 87 - 96
  • [10] Relationship Of Serum Free Light Chain Reduction To Best Overall Response In Phase 2 Single-Agent and Combination Studies Of Carfilzomib In Patients With Relapsed Or Relapsed and/Or Refractory Multiple Myeloma
    Vij, Ravi
    Wang, Michael
    Jagannath, Sundar
    Niesvizky, Ruben
    Jakubowiak, Andrzej J.
    Kavalerchik, Edward
    Huang, Mei
    Siegel, David S.
    [J]. BLOOD, 2013, 122 (21)
12345